- available. Elvitegravir/cobicistat/emtricitabine/tenofovir
alafenamide (
Genvoya) —
approved both in the
United States and in the
European Union in November...
-
Emtricitabine makes up one
fourth of the Quad pill (brand names:
Stribild and
Genvoya). It is also
marketed in a fixed-dose
combination with
tenofovir disoproxil...
-
Integrase inhibitor 2012 (Fixed-dose
combo Stribild) 2014 (single pill) 2015 (
Genvoya)
Emtricitabine HIV
Gilead Sciences NRTI 2003
Enfuvirtide HIV
Entry inhibitor...
- alafenamide, is
marketed as
Genvoya and was
approved by the FDA in
November 2015 for use in the
United States. Both
Stribild and
Genvoya are
owned by
Gilead Sciences...
- with HIV-1 as a part of a
second fixed dose
combination pill
known as
Genvoya.
According to the
results of the
phase II
clinical trial,
patients taking...
-
density loss. Gilead's
first TAF medication,
marketed under the
trade name
Genvoya, came out in 2015.
Lawsuits allege that in the
interim period, many HIV...
-
alafenamide instead of
tenofovir disoproxil is
offered under the
brand name
Genvoya (Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide). Dolutegravir...
-
therapies used to
treat HIV,
including Truvada, Atripla, Complera, Stribild,
Genvoya, Odefesey, Biktarvy, Descovy, and Symtuza.
Truvada is the only combination...
- drug regimens,
including Truvada, Atripla, Complera, Stribild, Descovy,
Genvoya, Odefsey, Descovy, Biktarvy, and Symtuza. Like 3TC, FTC was
found to be...
-
development of
Gilead Sciences' Stribild, Complera, TAF (Tenofovir Alfonamide),
Genvoya,
Odefsey and GS 9883, as well as Merck's non-nucleoside
reverse transcriptase...
